Literature DB >> 19768684

Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.

Amit Priyadarshi1, Eunice Eunkyeong Kim, Kwang Yeon Hwang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19768684     DOI： 10.1002/prot.22581

Source DB:  PubMed          Journal:  Proteins        ISSN： 0887-3585


× No keyword cloud information.
  19 in total

1.  Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).

Authors:  Jiangwei Yao; John B Maxwell; Charles O Rock
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

2.  Structure of the Francisella tularensis enoyl-acyl carrier protein reductase (FabI) in complex with NAD(+) and triclosan.

Authors:  Shahila Mehboob; Kent Truong; Bernard D Santarsiero; Michael E Johnson
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-10-27

3.  Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.

Authors:  Jiangwei Yao; Yasser M Abdelrahman; Rosanna M Robertson; John V Cox; Robert J Belland; Stephen W White; Charles O Rock
Journal:  J Biol Chem       Date:  2014-06-23       Impact factor: 5.157

4.  Crystal structures and kinetic properties of enoyl-acyl carrier protein reductase I from Candidatus Liberibacter asiaticus.

Authors:  Ling Jiang; Zengqiang Gao; Yanhua Li; Shennan Wang; Yuhui Dong
Journal:  Protein Sci       Date:  2014-02-12       Impact factor: 6.725

5.  High-resolution structures of Thermus thermophilus enoyl-acyl carrier protein reductase in the apo form, in complex with NAD+ and in complex with NAD+ and triclosan.

Authors:  José M Otero; Ann Josée Noël; Pablo Guardado-Calvo; Antonio L Llamas-Saiz; Wolfgang Wende; Benno Schierling; Alfred Pingoud; Mark J van Raaij
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-09-22

6.  Rational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA.

Authors:  Cheng-Tsung Lai; Huei-Jiun Li; Weixuan Yu; Sonam Shah; Gopal R Bommineni; Victoria Perrone; Miguel Garcia-Diaz; Peter J Tonge; Carlos Simmerling
Journal:  Biochemistry       Date:  2015-07-24       Impact factor: 3.162

7.  The genome of a Bacteroidetes inhabitant of the human gut encodes a structurally distinct enoyl-acyl carrier protein reductase (FabI).

Authors:  Christopher D Radka; Matthew W Frank; Jiangwei Yao; Jayaraman Seetharaman; Darcie J Miller; Charles O Rock
Journal:  J Biol Chem       Date:  2020-04-21       Impact factor: 5.157

8.  Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.

Authors:  Tina L Mistry; Lena Truong; Arun K Ghosh; Michael E Johnson; Shahila Mehboob
Journal:  ACS Infect Dis       Date:  2016-10-27       Impact factor: 5.084

9.  Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.

Authors:  Johannes Schiebel; Andrew Chang; Sonam Shah; Yang Lu; Li Liu; Pan Pan; Maria W Hirschbeck; Mona Tareilus; Sandra Eltschkner; Weixuan Yu; Jason E Cummings; Susan E Knudson; Gopal R Bommineni; Stephen G Walker; Richard A Slayden; Christoph A Sotriffer; Peter J Tonge; Caroline Kisker
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

10.  Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor.

Authors:  Nachum Kaplan; Monique Albert; Donald Awrey; Elias Bardouniotis; Judd Berman; Teresa Clarke; Mandy Dorsey; Barry Hafkin; Jaillal Ramnauth; Vladimir Romanov; Molly B Schmid; Rosanne Thalakada; Jeremy Yethon; Henry W Pauls
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.